Apicomplexa, trypanosoma and parasitic nematode protein kinases as antiparasitic therapeutic targets

Fina Liotta, John Siekierka

Research output: Contribution to journalReview articleResearchpeer-review

15 Citations (Scopus)

Abstract

Parasitic infections caused by Plasmodium, Trypanosoma, Leishmania, Toxoplasma and parasitic nematodes affect hundreds of millions of individuals worldwide and are the cause of significant mortality and morbidity, particularly in developing countries. These diseases also have an impact on individuals from developed countries; for example, some US troops in Iraq and Afghanistan have been infected with Leishmania. The annual mortality associated with parasitic infections is estimated to be 1.5 million deaths. The socioeconomic impact of the morbidity associated with parasitic infections is significant, and the development of new drugs, aimed at novel targets, is urgently needed to develop effective treatments for these diseases. The small-molecule inhibitors discussed in this review constitute useful tools with which to explore the relevance of kinase inhibition in inducing antiparasitic activity. The aim of recent target-based approaches used in the development of parasite kinase inhibitors is to identify novel antiparasitic agents with therapeutic potential.

Original languageEnglish
Pages (from-to)147-156
Number of pages10
JournalCurrent Opinion in Investigational Drugs
Volume11
Issue number2
StatePublished - 1 Feb 2010

Fingerprint

Apicomplexa
Trypanosoma
Antiparasitic Agents
Parasitic Diseases
Protein Kinases
Leishmania
Phosphotransferases
Morbidity
Afghanistan
Iraq
Plasmodium
Mortality
Toxoplasma
Developed Countries
Developing Countries
Parasites
Therapeutics
Pharmaceutical Preparations

Keywords

  • Helminthic disease
  • Leishmaniasis
  • Protein kinase
  • Synthetic inhibitor
  • Toxoplasma
  • Trypanosomiasis

Cite this

@article{61a6af334fa749d485c03d3ee1a29e60,
title = "Apicomplexa, trypanosoma and parasitic nematode protein kinases as antiparasitic therapeutic targets",
abstract = "Parasitic infections caused by Plasmodium, Trypanosoma, Leishmania, Toxoplasma and parasitic nematodes affect hundreds of millions of individuals worldwide and are the cause of significant mortality and morbidity, particularly in developing countries. These diseases also have an impact on individuals from developed countries; for example, some US troops in Iraq and Afghanistan have been infected with Leishmania. The annual mortality associated with parasitic infections is estimated to be 1.5 million deaths. The socioeconomic impact of the morbidity associated with parasitic infections is significant, and the development of new drugs, aimed at novel targets, is urgently needed to develop effective treatments for these diseases. The small-molecule inhibitors discussed in this review constitute useful tools with which to explore the relevance of kinase inhibition in inducing antiparasitic activity. The aim of recent target-based approaches used in the development of parasite kinase inhibitors is to identify novel antiparasitic agents with therapeutic potential.",
keywords = "Helminthic disease, Leishmaniasis, Protein kinase, Synthetic inhibitor, Toxoplasma, Trypanosomiasis",
author = "Fina Liotta and John Siekierka",
year = "2010",
month = "2",
day = "1",
language = "English",
volume = "11",
pages = "147--156",
journal = "Current Opinion in Investigational Drugs",
issn = "1472-4472",
publisher = "Current Drugs Ltd.",
number = "2",

}

Apicomplexa, trypanosoma and parasitic nematode protein kinases as antiparasitic therapeutic targets. / Liotta, Fina; Siekierka, John.

In: Current Opinion in Investigational Drugs, Vol. 11, No. 2, 01.02.2010, p. 147-156.

Research output: Contribution to journalReview articleResearchpeer-review

TY - JOUR

T1 - Apicomplexa, trypanosoma and parasitic nematode protein kinases as antiparasitic therapeutic targets

AU - Liotta, Fina

AU - Siekierka, John

PY - 2010/2/1

Y1 - 2010/2/1

N2 - Parasitic infections caused by Plasmodium, Trypanosoma, Leishmania, Toxoplasma and parasitic nematodes affect hundreds of millions of individuals worldwide and are the cause of significant mortality and morbidity, particularly in developing countries. These diseases also have an impact on individuals from developed countries; for example, some US troops in Iraq and Afghanistan have been infected with Leishmania. The annual mortality associated with parasitic infections is estimated to be 1.5 million deaths. The socioeconomic impact of the morbidity associated with parasitic infections is significant, and the development of new drugs, aimed at novel targets, is urgently needed to develop effective treatments for these diseases. The small-molecule inhibitors discussed in this review constitute useful tools with which to explore the relevance of kinase inhibition in inducing antiparasitic activity. The aim of recent target-based approaches used in the development of parasite kinase inhibitors is to identify novel antiparasitic agents with therapeutic potential.

AB - Parasitic infections caused by Plasmodium, Trypanosoma, Leishmania, Toxoplasma and parasitic nematodes affect hundreds of millions of individuals worldwide and are the cause of significant mortality and morbidity, particularly in developing countries. These diseases also have an impact on individuals from developed countries; for example, some US troops in Iraq and Afghanistan have been infected with Leishmania. The annual mortality associated with parasitic infections is estimated to be 1.5 million deaths. The socioeconomic impact of the morbidity associated with parasitic infections is significant, and the development of new drugs, aimed at novel targets, is urgently needed to develop effective treatments for these diseases. The small-molecule inhibitors discussed in this review constitute useful tools with which to explore the relevance of kinase inhibition in inducing antiparasitic activity. The aim of recent target-based approaches used in the development of parasite kinase inhibitors is to identify novel antiparasitic agents with therapeutic potential.

KW - Helminthic disease

KW - Leishmaniasis

KW - Protein kinase

KW - Synthetic inhibitor

KW - Toxoplasma

KW - Trypanosomiasis

UR - http://www.scopus.com/inward/record.url?scp=77649102440&partnerID=8YFLogxK

M3 - Review article

VL - 11

SP - 147

EP - 156

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1472-4472

IS - 2

ER -